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Three genetic loci for lung cancer risk have been identiﬁed by genome-wide association studies (GWAS), but inherited susceptibility to
speciﬁc histologic types of lung cancer is not well established. We conducted a GWAS of lung cancer and its major histologic types, gen-
otyping 515,922 single-nucleotide polymorphisms (SNPs) in 5739 lung cancer cases and 5848 controls from one population-based case-
control study and three cohort studies. Results were combined with summary data from ten additional studies, for a total of 13,300 cases
and 19,666 controls of European descent. Four studies also provided histology data for replication, resulting in 3333 adenocarcinomas
(AD), 2589 squamous cell carcinomas (SQ), and 1418 small cell carcinomas (SC). In analyses by histology, rs2736100 (TERT), on chro-
mosome 5p15.33, was associated with risk of adenocarcinoma (odds ratio [OR] ¼ 1.23, 95% conﬁdence interval [CI] ¼ 1.13–1.33, p ¼
3.023 107), but not with other histologic types (OR¼ 1.01, p¼ 0.84 and OR¼ 1.00, p¼ 0.93 for SQ and SC, respectively). This ﬁnding
was conﬁrmed in each replication study and overall meta-analysis (OR¼ 1.24, 95% CI¼ 1.17–1.31, p¼ 3.743 1014 for AD; OR¼ 0.99,
p¼ 0.69 andOR¼ 0.97, p¼ 0.48 for SQ and SC, respectively). Other previously reported association signals on 15q25 and 6p21were also
reﬁned, but no additional loci reached genome-wide signiﬁcance. In conclusion, a lung cancer GWAS identiﬁed a distinct hereditary
contribution to adenocarcinoma.
Recently, three genome-wide association studies (GWAS)
of lung cancer and subsequent pooled GWAS analyses
identiﬁed inherited susceptibility variants on chromosome
15q25,1–3 5p15,4–6 and 6p21.5 Lung cancer is classiﬁed
into two main histologic groups: small cell lung cancer
(SC) and non-small cell lung cancer; the latter includes
1Division of Cancer Epidemiology, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD
20892, USA; 2Information Management Services, Inc., Rockville, MD 20852, USA; 3Center for Health Sciences, Molecular Genetic Program, SRI Interna-
tional, Menlo Park, CA 94025, USA; 4Key Laboratory of Systems and Control, Academy of Mathematics and System Science, Chinese Academy of Science,
Beijing 100190, P.R. China; 5Unit of Epidemiology, Fondazione Istituto di Ricevero e Cura a Carattere Scientiﬁco, Ospedale Maggiore Policlinico, Mangi-
agalli e Regina Elena and Department of Occupational and Environmental Health, University of Milan, Milan, 20122, Italy; 6American Cancer Society,
Epidemiology and Surveillance Research, Atlanta, GA 30301, USA; 7Hubert H. Humphrey Cancer Center, Robbinsdale, University of Minnesota, Minneap-
olis, MN 55455, USA; 8Department of Chronic Disease Prevention, National Institute for Health and Welfare, Helsinki, 00280, Finland; 9Center for
Inherited Disease Research, Institute of Genetic Medicine, Johns Hopkins School of Medicine, Baltimore, MD 21224, USA; 10Department of Biostatistics,
University of Washington, Seattle, WA 98195, USA; 11International Agency for Research on Cancer, Lyon, 69372, France; 12Samuel Lunenfeld Research
Institute, Division of Epidemiology, Dalla Lana School of Public Health, University of Toronto, Toronto, ON M5T 3L9, Canada; 13Fondation Jean Daus-
set-Centre d’Etude du Polymorphisme Humain (CEPH), Paris, 75010, France; 14Department of Pathology, University Health Network, Princess Margaret
Hospital and University of Toronto, Toronto, ON M5T 3L9, Canada; 15Department of Epidemiology, M.D. Anderson Cancer Center, University of Texas,
Houston, TX 77030, USA; 16Section of Cancer Genetics, Institute of Cancer Research, Surrey, SM2 5NG, UK; 17Faculty of Medicine, Norwegian University
of Science and Technology, Trondheim, N-7489, Norway; 18Department of Community Medicine, University of Tromso, Tromso, N-9037, Norway;
19INSERM and Fondation Jean Dausset-CEPH, Paris, 75010, France; 20Geneva Cancer Registry, Geneva, 1205, Switzerland; 21Institute of Molecular and
Cell Biology and Estonian Genome Project of the University of Tartu, Estonian Biocentre, Tartu, 51010, Estonia; 22Roy Castle Lung Cancer Research
Program, The University of Liverpool Cancer Research Center, Liverpool, L3 97A, UK; 23Public Health Sciences Division, Fred Hutchinson Cancer Research
Center, Seattle, WA 98109, USA; 24deCODE Genetics, Reykjavik, 101, Iceland; 25Department of Oncology, University of Cambridge, Cambridge, CB2 2RE,
UK; 26Institute of Epidemiology, Helmholtz Center Munich, German Research Center for Environmental Health, Neuherberg, D-85764, Germany; 27Insti-
tute of Medical Informatics, Biometry and Epidemiology, Chair of Epidemiology, 28KlinikumGrosshadern, LudwigMaximilians University, 81377Munich,
Germany; 29Department of Genetic Epidemiology, University of Go¨ttingen Medical School, Go¨ttingen, D-37073, Germany; 30Division of Epigenomics and
Cancer Risk Factors, German Cancer Research Center, Heidelberg, D-69120, Germany
*Correspondence: landim@mail.nih.gov
DOI 10.1016/j.ajhg.2009.09.012. ª2009 by The American Society of Human Genetics. All rights reserved.
The American Journal of Human Genetics 85, 679–691, November 13, 2009 679
Table 1. Studies Included in the Genome-wide Association Analysis of Lung Cancer
No. of Subjects
Study Cases Controls Location Study Design Illumina HumanHap Chips
NCI GWAS
EAGLEa 1920 1979 Italy Population-based case-control 550K, 610QUAD
ATBCb 1732 1271 Finland Cohort 550K, 610QUAD
PLCOc 1390 1924 10 US Centers Cohort–Cancer Prevention Trial 317Kþ240S, 550K, 610QUAD
CPS-IId 697 674 All US States Cohort 550K, 610QUAD, 1M
TOTAL 5739 5848
Meta-Analysis
UK 1978 1438 UK Hospital-based cases,
birth cohort controls
550K
Central Europe 1837 2432 Romania, Hungary, Slovakia,
Poland, Russia, Checz Rep.
Multicenter hospital-based
case-control
317K, 370Duo
Texas 1154 1137 Texas, USA Hospital-based case-control 317K
DeCODE Genetics 719 6030 Iceland Population-based case-control 317K, 370Duo
HGF Germanye 506 480 Germany Population-based case-control
(<50 years)
550K
CARETf 397 393 6 US Centers Cancer Prevention Trial 370Duo
HUNT2/Tromsog 394 382 Norway Population-based case-control 370Duo
Canada 332 505 Greater Toronto area Hospital-based case-control 317K
France 135 146 Paris and Caen areas Hospital-based case-control 370Duo
Estonia 109 874 Estonia Hospital-based case-control 317K, 370Duo
TOTAL 7561 13818
Grand Total 13300 19666
a Environment and Genetics in Lung Cancer Etiology study.
b Alpha-Tocopherol, Beta-Carotene Cancer Prevention study.
c Prostate, Lung, Colon, Ovary screening trial.
d Cancer Prevention Study II nutrition cohort.
e Helmholtz-Gemeinschaft Deutscher Forschungszentren Lung Cancer GWAS.
f Carotene and Retinol Efficacy Trial cohort.
g North Trondelag Health Study 2 / Tromsø IV.adenocarcinoma (AD) and squamous cell carcinoma (SQ),
along with rarer subtypes. Worldwide, adenocarcinoma is
themost frequently identiﬁed histologic type, and the rela-
tive proportion of lung cancer due to this histology has
steadily risen. Demographic, etiologic, clinical, and molec-
ular characteristics of the lung cancer subtypes have been
reported.7 Although family history of lung cancer has
been associated with histologic subtypes,8–11 the inherited
susceptibility factors that affect speciﬁc histologies are
unknown.
We conducted a GWAS in 5739 lung cancer cases and
5848 controls (National Cancer Institute [NCI] GWAS)
to search for overall susceptibility variants and variants
associated with speciﬁc histologic types and smoking
status. We also conducted a meta-analysis of the NCI
GWAS with summary data from ten additional studies,
for a total of 13,300 primary lung cancer cases and
19,666 controls, all of European descent. Four of the ten
studies provided information on histology for replication680 The American Journal of Human Genetics 85, 679–691, Novemanalyses; 3333 AD, 2589 SQ, and 1418 SC cases were
analyzed overall.
The 11,587 subjects in the NCI GWAS were drawn from
one population-based case-control study and three cohort
studies (Table 1); speciﬁcally: the Environment and
Genetics in Lung Cancer Etiology (EAGLE),12 a popula-
tion-based case-control study including 2100 primary
lung cancer cases and 2120 healthy controls enrolled in
Italy between 2002 and 2005; the Alpha-Tocopherol,
Beta-Carotene Cancer Prevention Study (ATBC),13
a randomized primary prevention trial including 29,133
male smokers enrolled in Finland between 1985 and
1993; the Prostate, Lung, Colon, Ovary Screening Trial
(PLCO),14 a randomized trial including 150,000 individ-
uals enrolled in ten U.S. study centers between 1992 and
2001; and the Cancer Prevention Study II Nutrition Cohort
(CPS-II),15 including over 183,000 subjects enrolled by the
American Cancer Society between 1992 and 2001 across all
U.S. states. Analyses stratiﬁed by histology in the NCIber 13, 2009
GWAS included 1730 AD cases, 1400 SQ cases, 678 SC
cases, and groups of other histological types or of mixed
histologies. These studies were approved by the individual
institutional review boards of each location, and each
subject gave his or her informed consent for participation.
The meta-analysis included all of the NCI GWAS data
plus summary data from ten additional studies contrib-
uting 7561 cases and 13,818 controls (Table 1): (1) the
UK study from the Institute for Cancer Research,5
including lung cancer cases from the Genetic Lung Cancer
Predisposition Study established in 1999 and controls from
the 1958 birth cohort;16 (2) the International Agency for
Research on Cancer (IARC) study in central Europe,1 a
hospital-based case-control study conducted in the Czech
Republic, Hungary, Poland, Romania, Russia, and Slovakia
between 1998 and 2002; (3) the Texas case-control study,2
including cases newly diagnosed at the University of Texas
M.D. Anderson Cancer Center since 1991 and controls
from the Kelsey-Seybold clinics (the GWAS included only
smokers and cases with non-small cell lung cancer); (4)
the population-based case-control study from deCODE
Genetics in Iceland,3 including all Icelandic subjects origi-
nally recruited for different genetic studies between 1996
and 2007 at deCODE Genetics and lung cancer cases
recruited from the Icelandic Cancer Registry since 1998;
(5) the Helmholtz-Gemeinschaft Deutscher Forschungs-
zentren (HGF) lung cancer GWA study,17 including lung
cancer cases diagnosed at % 50 years from the LUng
Cancer in the Young (LUCY) study, a multicenter study
within 31 German hospitals, and the Heidelberg lung
cancer study, a hospital-based case-control study con-
ducted by the German Cancer Research Center (DKFZ)
(controls were selected from the Cooperative Health
Research in the Region of Augsburg [KORA]); (6) the Caro-
tene and Retinol Efﬁcacy Trial (CARET) cohort,18 including
smokers with a smoking history of at least 20 pack-years
enrolled in six U.S. centers between 1983 and 1994; (7)
the HUNT2/Tromso study, including lung cancer cases
and controls from the North Trondelag Health Study
(HUNT 2),19 a population-based study conducted between
1995 and 1997 in North Trondelag County, and the
Tromsø IV population-based study conducted in Tromsø
County between 1994 and 1995; 8) the lung cancer study
from Canada,1 including lung cancer cases recruited at the
University of Toronto and the Samuel Lunenfeld Research
Institute between 1997 and 2002 and GWAS controls
randomly selected from family medicine clinics; 9) the
lung cancer study from France,20 a hospital-based case-
control study including smoking cases and controls
recruited between 1988 and 1992 in ten French hospitals;
and 10) the lung cancer study from Estonia, a hospital-
based case-control study including lung cancer cases
enrolled between 2002 and 2006 in Estonian hospitals
and controls randomly selected from the Estonian
Genome Project population-based cohort.21
Three studies (the Texas,2 deCODE,3 and HGF German17
studies) also contributed summary data from genome-wideThe Americascans stratiﬁed by histology, including 1138 AD, 578 SQ,
and 210 SC cases. The UK study5 contributed data on the
top single nucleotide polymorphisms (SNPs) of chromo-
some 5p15.33 by histology. These four studies contributed
1603 AD, 1189 SQ, and 740 SC cases to the meta-analysis
by histology for this locus.
In both the NCI GWAS and the studies in the meta-anal-
ysis, the lung cancer diagnosis was based on clinical criteria
and conﬁrmed by pathology reports from surgery, biopsy,
or cytology samples in approximately 95% of cases and
on clinical history and imaging for the remaining 5%.
Tumor histology was coded according to the International
Classiﬁcation of Diseases for Oncology. In analyses strati-
ﬁed by histology, only adenocarcinoma, squamous cell
carcinoma, and small cell carcinoma cases were included.
All mixed subtypes or other histologies were excluded.
Overall, between 10% and 50% of all diagnoses from the
NCI GWAS were centrally reviewed by expert lung pathol-
ogists from NCI.
The NCI GWAS scan was conducted at two institutions:
the Center for Inherited Disease Research (CIDR), which
genotyped all EAGLE and 1675 PLCO subjects, and the
Core Genotyping Facility (CGF), NCI, which genotyped
ATBC, CPS-II, and the remaining PLCO subjects. Controls
from the Cancer Genetic Markers of Susceptibility
(CGEMS) prostate cancer scan22 were also included.
EAGLE samples and 1675 PLCO samples were genotyped
at CIDR, as part of the Gene Environment Association
Studies Initiative (GENEVA) funded through the National
Human Genome Research Institute, with the use of Illu-
mina HumanHap550v3_B BeadChips (Illumina, San
Diego, CA, USA). Data were released for 5620 of 5727
(98%) samples, including 32 blind duplicates (concor-
dance was 99.993%); these were genotyped with 124
HapMap controls (66 CEU; 58 YRI). Allele cluster deﬁni-
tions per SNP were determined with the use of the Illumina
BeadStudio Genotyping Module version 3.1.14 and the
combined intensity data from 95% of the samples. The re-
sulting cluster deﬁnitions were used on all samples. Geno-
types were not called if the quality threshold (Gencall
score) was below 0.15. Genotypes were released by CIDR
for 560,505 (99.83% of attempted) SNPs. Genotypes were
not released for SNPs not called by BeadStudio or for those
with call rates less than 85%,more than one HapMap repli-
cate error, more than a 3% (autosomal) or 5% (X chromo-
some) difference in call rate between genders, or more than
0.5%male AB frequency for the X chromosome. The mean
non-Y chromosome SNP call rate and mean sample call
rate were each 99.8% for the CIDR data set.
Similar procedures were followed at CGF for the ATBC,
CPSII, and PLCO cohorts with the use of three Illumina
platforms: the HumanHap550K, the HumanHap610, and
HumanHap 1 Million chips. All genotyped samples passed
quality control metrics at CGF. After removal of assay and
locus as a result of low completion rates, genotypes for
each sample that appeared in duplicate were merged to
form consensus genotypes for each subject. There weren Journal of Human Genetics 85, 679–691, November 13, 2009 681
12,111 study subjects available for subsequent analysis.
Table S1, available online, shows the distribution of
subjects by study and phenotype after application of
quality control (QC) metrics. Figure S1 shows the cluster
plot for the most notable SNP, rs2736100.
A total of 221 pairs of samples were identiﬁedwith>70%
genotype concordance rate. Among them, 189 pairs were
expected duplicates and had genotype concordance rates
> 99.9%. There were 12 unexpected duplicates (cross or
within studies)with>99.97%concordance rates.We evalu-
ated the pairwise concordance on the basis of the entire set
and observed 40 pairs of subjects with over 60% of concor-
dant genotypes (genotype concordance> 60%). Exclusions
are listed in Table S2. Deviations from Hardy-Weinberg
proportions (HWP) were assessed in controls. Expected
and observed p values were calculated with the use of the
uniform distribution for all loci and the exact test, respec-
tively. Autosomal SNPs with minor allele frequencies
(MAFs) >5% and completion rates >95% were included.
Deviation from HWP was minimal, and only loci with
extremely low p values (p < 107) for each QC group were
excluded from further analyses (Table S3). A quantile-quan-
tile (Q-Q)plotof thepvaluesper study is showninFigure S2.
To assess population structure, we estimated imputed
continental ancestry by using the STRUCTURE program,23
with a set of 12,898 autosomal SNPs with low local back-
ground linkage disequilibrium (LD) (pairwise r2 < 0.004
measured in the population of European ancestry for any
pair of SNPs less than 500 kb apart)24 (Figure S3). Geno-
types from the three HapMap populations (Build 22 for
HapMap II with MAF > 5%)25 were used as reference pop-
ulations. The number of inferred clusters (‘‘K’’ parameter)
was set to 3 for CEU, YRI, and JPTþCHB samples represent-
ing populations of European, African, and Asian origin,
respectively. Eighteen subjects were detected as having
less than 80% European ancestry and were excluded.
Principal component analysis (PCA) for each study
group (excluding subjects with less than 80% European
ancestry, unexpected duplicates, and potential relative
pairs) was performed with the same informative 12,898
SNPs with the use of the EIGENSTRAT program26 (Figures
S4A–S4D). After adjustment for signiﬁcant principal
components (PCs) in each study, comparison of observed
and expected distributions showed no evidence for large-
scale inﬂation of the association test statistics (inﬂation
factor l ¼ 1.03, 103, 1.01, and 1.01 in EAGLE, PLCO,
CPS-II, and ATBC, respectively), excluding the possibility
of signiﬁcant hidden population substructure. Q-Q plots
for each NCI study are shown in Figures S5A–S5D.
After excluding 183 subjects for the reasons described
above (summarized in Table S2) and 337 subjects with
incomplete phenotype data, we report analyses on
515,922 SNPs in 5739 lung cancer cases and 5848 controls
(NCI GWAS, Table 1).
Comparable QC procedures were conducted at each
institution that provided summary results for the meta-
analysis.1–5682 The American Journal of Human Genetics 85, 679–691, NovemFor the genome-wide analysis of the NCI GWAS, we used
unconditional logistic regression to derive a per-allele odds
ratio (OR) and an associated 1 degree of freedom (df) asso-
ciation test adjusted for age in ﬁve-year intervals (deﬁned
as age at diagnosis or interview for the case-control study
and as baseline age for cohort studies), gender, study
(EAGLE, PLCO, ATBC, ACS), and four PCs for population
stratiﬁcation within studies (see description of PC analysis
below). In additional analyses, we adjusted for smoking
status (current, former, never), cigarettes smoked per day
(% 10, 11–20, 21–30, 31–40, 41þ), duration in 10 yr inter-
vals, and number of years since quitting (1–5, 6–10, 11–20,
21–30, 30þ) for former smokers (subjects who quit
smoking at least 6 mo before participating in the study).
The analyses with single and multiple SNPs stratiﬁed by
histology, smoking status, and decade of birth were con-
ducted with the use of the same models. Tests for interac-
tion between a SNP (coded as a continuous variable) and
smoking status or birth decade (coded with the use of
dummy variables) were performed with Wald tests with
the use of multiple dfs.
For the meta-analysis with other studies, we obtained
per-allele ORs and standard errors from each study. Because
only summary data were available, we conducted the
meta-analysis in two separate groups: ‘‘Set 1 SNPs’’
included a core of 279,698 SNPs that were available across
all studies; and ‘‘Set 2 SNPs’’ included 197,647 SNPs that
were available only for a subset of the studies that used
the HumanHap500 or denser genomic platforms or
provided summary data on imputed SNPs. We obtained
meta-analysis estimates of per-allele ORs and associated
p values by using the weighted Z-score method under
a ﬁxed effect model.27 Tests for heterogeneity by study
were performed with the use of the QE statistics, assuming
a random effect model. For testing of heterogeneity across
histologic subtypes, we reported the smallest p values
obtained from pairwise case-case analyses between the
subtypes after adjustment for multiple testing with the
use of the Bonferroni correction. All odds-ratios were
reported with respect to the minor allele in the pooled
set of controls from all studies that contributed to the
meta-analysis.
For adjustment of population stratiﬁcation, we used the
same set of 12,898 autosomal informative SNPs24 used for
QC. We conducted PCA in each of the four study groups
(EAGLE, PLCO, ATBC, and CPS-II) separately.27 For each
study group, we identiﬁed among the top ten PCs the
ones on which lung cancer cases and controls were not
distributed evenly (the Wilcoxon rank-sum test p < 0.1),
and adjusted them as continuous covariates nested within
each study group. We selected two PCs for PLCO and one
for each EAGLE and ATBC. No PCs were selected for the
CPS-II study. Of note, we replicated the major analyses
by using PCs obtained from all SNPs and found virtually
identical results (data not shown).
Genome-wide analysis of the NCI GWAS conﬁrmed
previously reported ﬁndings on 5p15, 15q25, and 6p21,ber 13, 2009
but did not conclusively identify novel susceptibility loci
for lung cancer risk. Similar results were obtained in the
overall meta-analysis combining the NCI GWAS with
results from the ten additional studies, for a total of over
30,000 subjects (Figure 1 and Table S5).
The analysis of the locus on the 5p15.33 region4–6
provided notable ﬁndings. In the overall analysis of the
NCI GWAS, the most prominent SNPs were rs4635969
(OR ¼ 0.87, 95% conﬁdence interval [CI] ¼ 0.82–0.93,
p ¼ 9.80 3 105), followed by rs31489 in CLPTM1L (also
named CCR9 [MIM 612585]) (OR ¼ 0.90, 95% CI ¼
0.86–0.95, p ¼ 2.80 3 104) and rs2736100 in TERT
(MIM 187270) (OR ¼ 1.09, 95% CI ¼ 1.03–1.15, p ¼
0.001) (Table 2). rs2736100 showed discrepant results by
smoking status (Table 2), which reﬂected different associa-
tions across histologies. In fact, this locus showed remark-
able differences by histology (Figure 2). The rs2736100 SNP
was associated only with AD (OR ¼ 1.23, 95% CI ¼ 1.13–
1.33, p ¼ 3.02 3 107), but not the other histologic types
(OR ¼ 1.01, p ¼ 0.84 and OR ¼ 1.00, p ¼ 0.93, for SQ
and SC, respectively; p ¼ 0.001, test for heterogeneity
across histologies corrected for multiple comparisons).
The risk estimates were not altered by the adjustment for
smoking and were consistent across categories of smoking
intensity and decade of birth (data not shown). The anal-
ysis by smoking status (Table 2) revealed that the SNP
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Figure 1. ‘‘Manhattan Plot’’ of Meta-Analysis Results for Lung
Cancer Susceptibility Loci
Genome-wide association results for 13,300 primary lung cancer
cases and 19,666 controls. Log10 p values plotted against the
chromosomal positions are depicted. ‘‘Set 1 SNPs’’ includes the
core of 279,698 SNPs that were available across all studies. ‘‘Set 2
SNPs’’ includes 197,647 SNPs that were available only for a subset
of the studies that used HumanHap500 or denser genomic plat-
forms or provided summary data on imputed SNPs. The plot has
been truncated at p < 1010. There were 37 additional SNPs with
lower p values, which are included in the list of the top 200
SNPs reported in Table S5.The Americawas signiﬁcantly associated with risk of adenocarcinoma
in both smokers and those who had never smoked.
In the NCI controls, rs2736100 is not in LD with other
tested SNPs in the region (Figure 2), with the exception
of rs2853676, which is in modest LD (r2 ¼ 0.25, D0 ¼
0.82) and showed a similar pattern of association (OR ¼
1.16, p¼ 3.443 104; OR¼ 0.95, p¼ 0.30; and OR¼ 1.06,
p ¼ 0.41 for AD, SQ, and SC, respectively). In contrast,
rs4635969 and rs31489 were associated with lung cancer
risk across histology groups (Table 2). The previously
reported SNPs in CLPTM1L, e.g., rs4975616, rs402710,
and rs401681, which are in LD with rs31489 (r2 ¼ 0.74,
0.63, and 0.85, respectively), showed associations similar
to rs31489 (data not shown). rs31489 and rs4635969 are
moderately correlated (r2 ¼ 0.35, D0 ¼ 0.95), but not in
LD with rs2736100 (r2 ¼ 0.03, D0 ¼ 0.20 for rs31489; r2 ¼
0.07, D0 ¼ 0.49 for rs4635969). In a multivariate model
including the main effects of these three SNPs simulta-
neously, we found statistically independent associations
with AD for both rs4635969 and rs2736100 (OR ¼ 0.81,
p ¼ 0.002; OR ¼ 1.21, p ¼ 2.60 3 105) but not for
rs31489 (OR ¼ 1.03, p ¼ 0.42). Only rs31489 was associ-
ated with SQ (OR ¼ 0.82, p ¼ 8.50 3 104) and no SNPs
were associated with SC (data not shown) in the multivar-
iate model.
In the meta-analysis, rs2736100 was the most notable
SNP for lung cancer risk overall (OR ¼ 1.12, 95% CI ¼
1.08–1.16, p ¼ 1.60 3 1010), followed by the same set of
SNPs observed in the NCI GWAS (Table 2, larger list in
Table S5). In analyses by histology, risk associated with
rs2736100 was accounted for by cases with adenocarci-
noma in each replication study (p < 0.05 in each study;
p ¼ 0.59, test for heterogeneity across studies) (Figure 3).
Other histologies exhibited no association. In the meta-
analysis combining the NCI GWAS data with the data
from the Texas, deCODE, HGF, and UK studies, this SNP
had OR ¼ 1.24, 95% CI ¼ 1.17–1.31, p ¼ 3.74 3 1014
for AD versus OR ¼ 0.99, p ¼ 0.69 and OR ¼ 0.97, p ¼
0.48, for SQ and SC, respectively (Table 2).
These ﬁndings provide evidence that thepreviously iden-
tiﬁed association of the rs2736100 variant on 5p15.33
with lung cancer risk4,5 is conﬁned to one histologic type,
adenocarcinoma. Rs2736100 is located in intron 2 of
TERT and, on the basis of the ESPERR score, lies within
a putative regulatory region.28 TERT is a ribonucleoprotein
that extends TTAGGG nucleotide repeats at the telomere,
which shortenwith each cell division. Telomere shortening
is associatedwith increased genomic instability and, conse-
quently, increased risk of cancer development.29 In cancer
cells, reactivated TERT is linked to cellular proliferation
and abnormal telomere maintenance.30
Other studies have suggested that perturbations of TERT
may contribute to the pathogenesis of lung adenocarci-
noma.TERTexpressionhasbeen reported tobe signiﬁcantly
lower in adenocarcinoma than in any other histological
type,31 and its reexpression may indicate progression from
bronchiolo-alveolar carcinoma to adenocarcinoma.32,33n Journal of Human Genetics 85, 679–691, November 13, 2009 683
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0.93 (0.79, 1.09) 0.11 0.82 (0.64, 1.05)
0.77 (0.41, 1.44) 0.76 1.15 (0.47, 2.85)
5 0.87 (0.81, 0.92) 0.024 0.91 (0.83, 0.99)
0.88 (0.79, 0.99) 0.055 0.86 (0.74, 1.00)
0.89 (0.77, 1.03) 0.20 0.89 (0.74, 1.06)
0.88 (0.72, 1.07) 0.11 0.77 (0.56, 1.06)
1.21 (0.58, 2.52) 0.73 0.81 (0.23, 2.78)
0.88 (0.80, 0.96) 0.20 0.92 (0.80, 1.05)
12 1.36 (1.24, 1.48) 3.76 3 108 1.38 (1.23, 1.55)
8 1.38 (1.23, 1.55) 4.28 3 107 1.43 (1.25, 1.65)
5 1.39 (1.19, 1.62) 0.05 1.27 (1.00, 1.61)
0.94 (0.50, 1.75) 0.16 2.00 (0.76, 5.27)
13 1.30 (1.21, 1.40) 2.31 3 109 1.37 (1.24, 1.52)
9 1.31 (1.20, 1.43) 6.70 3 108 1.38 (1.23, 1.55)
1.34 (1.20, 1.50) 2.58 3 107 1.45 (1.26, 1.67)
1.32 (1.13, 1.54) 0.13 1.20 (0.95, 1.54)
1.13 (0.60, 2.11) 0.08 2.44 (0.91, 6.51)
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9Table 2. Association of Selected SNPs on 5p15 and 15q25 Loci with Lung Cancer Risk Overall and by Histologic Types and Smoking Sta
Marker,a Allele,b Location,c
Gene,d MAFe Study
Overall NCI Data Adenocarcinoma NCI Data
Squamou
Carcinom
p Valuef ORg (95% CI) p Valuef ORg (95% CI) p Valuef
SNPs on Chromosome 5p15
rs2736100, (T,G), 1339516,
TERT, 0.499/0.466
NCI_Smoking Unadjusted 0.001 1.09 (1.03, 1.15) 3.02 3 107 1.23 (1.13,1.33) 0.84
NCI_Current smokers 0.41 1.03 (0.96-1.11) 0.001 1.23 (1.09, 1.39) 0.37
NCI_Former smokers 0.02 1.11 (1.02, 1.22) 0.01 1.17 (1.03, 1.33) 0.13
NCI_Never smokers 0.002 1.34 (1.11, 1.61) 0.01 1.35 (1.07, 1.71) 0.33
Meta-analysis Unadjusted 1.60 3 10-10 1.12 (1.08, 1.16) 3.74 3 10-14 1.24 (1.17, 1.31) 0.69
rs31489, (C,A), 1395714,
CLPTM1L, 0.411/0.385
NCI_Smoking Unadjusted 2.80 3 10-4 0.90 (0.86, 0.95) 0.067 0.93 (0.86, 1.00) 8.51 3 10-
NCI_Current smokers 0.008 0.90 (0.83-0.97) 0.21 0.92 (0.82, 1.05) 0.0003
NCI_Former smokers 0.33 0.95 (0.87, 1.05) 0.68 0.97 (0.86, 1.11) 0.35
NCI_Never smokers 0.37 0.92 (0.77, 1.10) 0.45 0.92 (0.73, 1.15) 0.41
Meta-analysis Unadjusted 1.56 3 1010 0.89 (0.86, 0.92) 0.005 0.92 (0.87, 0.98) 1.39 3 10
rs4635969, (C,T), 1361552,
TERT, CLPTM1L, 0.199/0.184
NCI_Smoking Unadjusted 9.80 3 105 0.87 (0.82, 0.93) 5.49 3 105 0.81 (0.73, 0.90) 0.031
NCI_Current smokers 0.08 0.92 (0.83, 1.01) 0.02 0.82 (0.70, 0.96) 0.12
NCI_Former smokers 0.001 0.83 (0.74, 0.93) 0.006 0.80 (0.68, 0.94) 0.20
NCI_Never smokers 0.27 0.88 (0.69, 1.11) 0.08 0.76 (0.56, 1.04) 0.61
Meta-analysis Unadjusted 2.15 3 108 0.88 (0.84, 0.92) 6.39 3 106 0.83 (0.77, 0.90) 0.005
SNPs on Chromosome 15q25
rs12914385, (C,T), 76685778,
CHRNA3, 0.386/0.452
NCI_Smoking Unadjusted 5.24 3 1027 1.34 (1.27, 1.42) 3.93 3 1014 1.36 (1.25, 1.47) 5.23 3 10
NCI_Current smokers 6.12 3 1018 1.41 (1.31, 1.53) 2.88 3 108 1.42 (1.25, 1.61) 2.12 3 10
NCI_Former smokers 6.11 3 1010 1.34 (1.22, 1.47) 5.65 3 107 1.38 (1.22, 1.57) 2.92 3 10
NCI_Never smokers 0.24 1.11 (0.93, 1.34) 0.24 1.15 (0.92, 1.46) 0.84
Meta-analysis Unadjusted 2.75 3 1038 1.30 (1.25, 1.36) 3.32 3 1018 1.31 (1.23, 1.40) 8.72 3 10
rs1051730, (C,T), 76681394,
CHRNA5,CHRNA3, 0.348/
0.413
NCI_Smoking Unadjusted 3.63 3 1025 1.33 (1.26, 1.41) 4.21x1014 1.36 (1.26, 1.47) 1.93x 10
NCI_Current smokers 1.30 3 1017 1.42 (1.31, 1.53) 1.03x108 1.44 (1.27, 1.63) 4.7x107
NCI_Former smokers 3.66 3 108 1.30 (1.19, 1.43) 8.05x10-7 1.38 (1.21, 1.57) 0.0005
NCI_Never smokers 0.14 1.15 (0.96, 1.38) 0.22 1.16 (0.92, 1.46) 0.71
carcinoma NCI Data
Squamous Cell
Carcinoma NCI Data:
Small Cell
Carcinoma NCI Data:
f ORg (95% CI) p Valuef ORg (95% CI) p Valuef ORg (95% CI)
1019 1.32 (1.24, 1.41) 1.01 3 1010 1.28 (1.18, 1.37) 3.18 3 109 1.37 (1.23, 1.52)
1010 1.30 (1.20, 1.40) 1.10 3 107 1.26 (1.16, 1.38) 1.31 3 105 1.29 (1.15, 1.45)
107 1.38 (1.22, 1.56) 2.49 3 105 1.27 (1.14, 1.43) 7.14 3 105 1.33 (1.15, 1.53)
105 1.33 (1.17, 1.51) 0.0004 1.32 (1.13, 1.54) 0.10 1.22 (0.96, 1.56)
1.04 (0.82, 1.31) 0.90 1.04 (0.56, 1.94) 0.11 2.21 (0.84, 5.82)
1015 1.29 (1.21, 1.37) 3.37 3 109 1.25 (1.16, 1.34) 4.49 3 107 1.31 (1.18, 1.45)
former, 362 never smokers). Meta-analysis: 19666 controls, 13300 cases
nt, 731 former, 203 never smokers). Meta-analysis: 14933 controls, 3333 cases
953 current, 422 former, 23 never smokers). Meta-analysis: 14933 controls, 2589 cases
rrent, 152 former, 9 never smokers). Meta-analysis: 13796 controls, 1418 cases
own. The lung cancer cases in the Overall analyses include adenocarcinomas, squamous cell carcinomas,
nclude four NCI GWAS studies plus ten additional studies; the meta-analyses in the three major histologic
ation studies for the SNPs on chromosome 15q25. Results for each SNP are shown in this order: Top row
t-diagnosis/interview for case-control study and age at baseline for cohort study), gender, study (EAGLE,
one each for EAGLE and ATBC). Adjustment for the same variables plus smoking status (current, former,
ears since quitting (1–5, 6–10, 11–20, 21–30, 30þ) for former smokers showed virtually identical results
ubjects, adjusted for the same variables of the top row. Third row (NCI_Former smokers), results from the
r the same variables of the top row. Fourth row (NCI_Never smokers), results from the NCI GWAS data
of the top row. Bottom row (Meta-analysis Unadjusted), results from the meta-analysis combining NCITable 2. Continued
Marker,a Allele,b Location,c
Gene,d MAFe Study
Overall NCI Data Adeno
p Valuef ORg (95% CI) p Value
Meta-analysis Unadjusted 1.91 3 1051 1.31 (1.27, 1.36) 7.10 3
rs8034191, (T,C), 76593078,
LOC123688, 0.352/0.414
NCI_Smoking Unadjusted 6.19 3 1020 1.29 (1.22, 1.36) 1.61 3
NCI_Current smokers 3.51 3 1014 1.36 (1.25, 1.47) 4.14 3
NCI_Former smokers 1.52 3 107 1.29 (1.17, 1.41) 1.33 3
NCI_Never smokers 0.72 1.03 (0.86, 1.24) 0.77
Meta-analysis Unadjusted 2.18 3 10-46 1.29 (1.25, 1.34) 1.46 3
Bold font indicates genome-wide significant results
Overall NCI Data: 5848 controls (2384 current, 2041 former,1402 never smokers), 5739 cases (3410 current, 1946
Adenocarcinoma NCI Data: 5848 controls (2384 current, 2041 former,1402 never smokers), 1730 cases (786 curre
Squamous Cell Carcinoma NCI Data: 5848 controls (2384 current, 2041 former,1402 never smokers), 1400 cases (
Small Cell Carcinoma NCI Data: 5848 controls (2384 current, 2041 former,1402 never smokers), 678 cases (516 cu
Most notable SNPs from the NCI GWAS and SNPs identified as relevant for lung cancer risk in previous studies are sh
small cell carcinomas, and other groups of different histologic types or mixed histologies. The Overall meta-analyses i
types include four NCI GWAS studies plus four replication studies for the SNPs on chromosome 5p15 and three replic
(NCI_Smoking Unadjusted), results from the NCI GWAS data adjusted for age in five-year intervals (defined as age-a
PLCO, ATBC, CPS-II) and four principal components for population stratification within studies (two for PLCO, and
never), cigarettes smoked per day (%10, 11–20, 21–30, 31–40, 41þ), duration in ten-year intervals and number of y
(data not shown). Second row (NCI_Current smokers), results from the NCI GWAS data restricted to current smoker s
NCI GWAS data restricted to former smoker subjects who quit smoking > 6 months prior to the study, adjusted fo
restricted to never smoker subjects who smoked < 100 cigarettes in their lifetime, adjusted for the same variables
GWAS data and ten additional studies, unadjusted models.
a NCBI dbSNP identifier.
b Major allele, minor allele.
c Chromosome and NCBI Human genome Build 36 location.
d Gene neighborhood within 20 kb upstream and 10 kb downstream of SNP.
e Minor allele frequency in controls/cases.
f 1d.f. Wald test.
g OR, per-allele odds ratio; CI, 95% confidence interval.
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TERT has been reported to promote epithelial prolifera-
tion,34 whereas telomere maintenance has been implicated
in the progression from KRAS-activated adenoma to adeno-
carcinoma in murine models.35 rs2736100 was recently
found in association with lung cancer risk in two popula-
tions, with suggestive stronger associations in adenocarci-
noma cases, female cases, and case individuals who had
never smoked.36,37 Interestingly, rs2736100 has been
reported tobe associatedwith susceptibility to sporadic idio-
pathic pulmonaryﬁbrosis (IPF),38,39whereas raremutations
in TERT and consequent shorter telomeres are responsible
for familial IPF.40 IPF is a lethal disease characterized by
massive ﬁbrotic changes and thickening of the alveolar
walls in the lung. Members of IPF families frequently
develop lung adenocarcinoma, suggesting that these two
diseases share a common etiology.41 Furthermore, telome-
rase dysfunction has been linked to leukemia, bonemarrow
failure, and cancer predisposition,42–44 and other SNPs in
the TERT-CLPTM1L region have been found in association
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Figure 2. Results of Association Analyses and LD Block for the
5p15.33 Locus by Histology
Association results are shown in the top panel for the NCI GWAS.
Results of the meta-analysis combining the NCI GWAS and the
additional four studies for rs2736100 in the adenocarcinoma
histologic type are indicated by the purple diamond. Red circles
indicate adenocarcinoma, blue triangles indicate squamous cell
carcinoma, and green circles indicate small cell carcinoma. At
the bottom, pairwise LD is depicted for 65 SNPs with minor allele
frequency >5% in the 5p15.33 region extending from 1204161 to
1496199. The LD among pairs of SNPs was characterized on the
basis of the square of the correlation coefﬁcient (r2) with the use
of EAGLE and PLCO controls of a European background (1997
from EAGLE and 859 from PLCO, totaling 2856 unrelated individ-
uals). Regions with high r2 values are red, and regions with low r2
values are light yellow. The shade lightens with decreasing r2. The
purple bar indicates the approximate location of the TERT gene.686 The American Journal of Human Genetics 85, 679–691, Novemwith multiple cancer types,6 suggesting that this region
possesses a fundamental key for cancer development.
rs2736100 and other SNPs in the locus are close to the loca-
tion of known mutations that compromise telomerase
activity (Figure 4) and may be in LD with mutations that
have yet to be identiﬁed. Complete sequencing of this locus
in adenocarcinoma patients would enable a more compre-
hensive understanding of the variants associated with this
signal.
The NCI GWAS also reﬁned other previously identiﬁed
susceptibility loci.1–3,5 The strongest evidence for associa-
tion with lung cancer risk overall and with each histology
group was observed for the 15q25.1 locus.1–3 (nicotinic
acetylcholine receptor genes), beginning with rs12914385
in CHRNA3 (MIM 118503) (OR ¼ 1.34, 95% CI ¼ 1.27–
1.42, p ¼ 5.24 3 1027) (Table 2; top SNPs with p <
0.0001 in each histologic group are shown in Tables
S6–S8). In the meta-analysis including the NCI GWAS and
summary results from ten studies, the SNP with the lowest
p value was rs1051730 in CHRNA5 (MIM 118505) (OR ¼
1.31, 95% CI ¼ 1.27–1.36, p ¼ 1.91 3 1051), whereas
rs12914385 had an OR ¼ 1.30, 95% CI ¼ 1.25–1.36, p ¼
2.75 3 1038 (Table 2; a longer SNP list in given in Table
S5). The same SNPs were also strongly associated with all
major histology groups (Table 2).
There were 20 SNPs at this locus with p < 107 and 15
after adjustment formultiple smoking variables, suggesting
that the association of these SNPs with lung cancer risk
is not entirely explained by the association with smoking
or that residual confounding by smoking cannot be
completely ruled out. In the analysis of theNCIGWAS strat-
iﬁed by smoking status (Table 2), SNPs on 15q25 showed
a very strong association in current and former smokers
butno association in thosewhohadnever smoked, as previ-
ously observed in some,2,45 but not all,1 studies. The inter-
action between these SNPs and smoking status was border-
line signiﬁcant (p ¼ 0.07, p ¼ 0.07, and p ¼ 0.04 for
rs12914385, rs1051730, and rs8034191, respectively).
We conducted an analysis stratiﬁed by decade of birth
(<1930, 1930–1939, 1940–1949, and >1950) to explore
whether the complex changes in cigarette composition
and population trends in cigarette smoking affected the
association between this locus and lung cancer risk. Most
subjects in our study were born in the 1930s–1940s and
began smoking approximately 15–20 years after birth.
Thus, smokers were affected by the progressive adoption
of cigarette ﬁlters and alterations in tar, nicotine, and
nitrosamine content in cigarettes that began in the
1950s.46 For the top SNPs on 15q25, we observed a trend
of increasing lung cancer risk with more recent decades
of birth both overall and in each histology group, with
the exception of the SQ cases (Table 3). Because widespread
cigarette smoking generally began a few years later in Eu-
rope than in the U.S., we stratiﬁed the analyses between
American (PLCO and CPS-II) and European (EAGLE and
ATBC) studies. As expected, the American studies showed
a slightly stronger association (data not shown).ber 13, 2009
Figure 3. Forest Plot Showing Associations
between the rs2736100 SNP and Lung Cancer
Risk Both Overall and by Histologic Types
Left panel: (A) Association between rs2736100
and lung cancer risk in each study included in
the NCI GWAS and in each additional study
contributing to the meta-analysis. Right panel:
(B) Association between rs2736100 and risk of
adenocarcinoma, (C) squamous cell carcinoma,
and (D) small cell carcinoma in the NCI GWAS
and in each additional study contributing to the
meta-analysis, stratiﬁed by histology. Individual
studies (boxes) are plotted against the individual
effect sizes (ORs). The size of the boxes is
inversely proportioned to the variance. Hori-
zontal lines indicate 95% CIs. The dashed vertical
line in each panel shows the value for no effect
(OR ¼1.0).The American Journal of Human Genetics 85, 679–691, November 13, 2009 687
One possible explanation for the increasing risk in more
recent decades of birth is that the association of chromo-
some 15q25 SNPs with lung cancer risk is mediated in
part by the increasing nitrosamine content in cigarettes
over the second half of the 20th century.47,48 Carcinogenic
nitrosamines are thought to bind to the nicotinic
receptor,49 and carriers of the 15q25 locus are exposed to
a higher internal dose of nitrosamines per cigarette than
are noncarriers.50 No clear trend by decade of birth was
observed for squamous cell carcinoma, possibly because
this histologic type is more strongly associated with
polycyclic aromatic hydrocarbons than with nitrosa-
mines.47,48,51 However, these ﬁndings may be affected by
small numbers in subgroups and should be further
explored.
A recent study from the UK reported that the 6p21.33
locus is associated with lung cancer risk,5 and a suggestive
association for another SNP in the region (rs4324798 on
6p22.1) had been previously shown.1 In the meta-analysis,
SNPs at this locus were associated with lung cancer risk
(Table S4). However, the association varied by study and
was weak in the NCI GWAS and in the studies used in repli-
cating the analysis by histology (Table S4). These SNPs are
located near the major histocompatibility complex and
thus could be markers for differences in population
substructure.
In this study including over 30,000 subjects, no new
genomic regions associated with lung cancer risk were
identiﬁed. This contrasts with studies of other cancer
types, such as breast, colon, and prostate cancers, which
observed multiple common susceptibility loci in similar
or smaller sample sizes.52–54 It is plausible that additional
genetic variation for smoking-related cancers will be
revealed through the investigation of interaction with
tobacco smoking or structural variants. Our ﬁndings are
based on subjects of European descent only; further work
is necessary for the exploration of whether additional
loci or different variants in the same loci are associated
with lung cancer risk in distinct populations.
In conclusion, we have established that a locus on chro-
mosome 5p15.33 is distinctly associated with risk of lung
adenocarcinoma and not with the other major histologic
types, providing evidence of histology-speciﬁc germ-line
susceptibility for lung cancer risk. Deﬁning the distinct
hereditary contribution to histological subtypes and their
interplay with tobacco smoking is a step on the pathway
to the molecular characterization of cancer and could lead
to improved measures for early detection or prevention.
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Figure 4. Location of SNPs and Mutations in the TERT Gene
Exon and intron organization of the TERT gene, including the locations of rs2736100, rs2853676, and the known mutations (red
asterisks) that compromise telomerase activity.39–44688 The American Journal of Human Genetics 85, 679–691, November 13, 2009
s ¼ 696) 1950þ (No. of Controls ¼ 190)
(95% CI)
No. of
Cases p Valuea ORb (95% CI)
Pint
c
SmokAdj
(1.20–1.66) 155 2.60 3 105 1.94 (1.42–2.64) 0.02
(1.19–1.74) 155 3.91 3 104 1.98 (1.36–2.88) 0.04
(1.12–1.80) 84 0.001 2.10 (1.33–3.32) 0.03
(0.95–1.92) 17 0.16 1.75 (0.80–3.85) 0.92
(1.31–3.09) 15 0.043 2.59 (1.03–6.51) 0.10
(1.21–1.68) 155 6.75 3 106 2.08 (1.51–2.86) 0.009
(1.15–1.70) 155 8.86 3 105 2.18 (1.48–3.23) 0.02
(1.09–1.75) 84 0.002 2.08 (1.30–3.31) 0.05
(0.84–1.72) 17 0.053 2.23 (0.99–5.05) 0.79
(1.37–3.28) 15 0.018 3.23 (1.22–8.53) 0.02
(1.20–1.67) 155 1.10 3 105 2.01 (1.47–2.74) 0.007
(1.16–1.70) 155 1.56 3 104 2.09 (1.43–3.06) 0.01
(1.14–1.84) 84 0.005 1.92 (1.22–3.02) 0.01
(0.82–1.67) 17 0.064 2.04 (0.96–4.35) 0.67
(1.23–2.91) 15 0.039 2.60 (1.05–6.44) 0.05
Overall analyses include adenocarcinomas, squamous cell carcinomas,
ervals (defined as age-at-diagnosis/interview for case-control study and
components for population stratification within studies (two for PLCO,
igarettes smoked per day (%10, 11–20, 21–30, 31–40, 41þ), duration
est (decade of birth coded as 0,1,2,3).
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9Table 3. Association of Selected SNPs on 15q25 Loci with Lung Cancer Risk by Decade of Birth in the NCI GWAS
Study
< 1930 (No. of Controls ¼ 1749) 1930–1939 (No. of Controls ¼ 2113) 1940–1949 (No. of Control
No. of
Cases p Valuea ORb (95% CI)
No. of
Cases p Valuea ORb (95% CI)
No. of
Cases p Valuea ORb
rs12914385
Overall Smok.Unadj 2202 6.94 3 108 1.29 (1.18–1.41) 2173 6.94 3 1012 1.35 (1.24–1.47) 594 2.49 3 105 1.42
Overall Smok.Adjust 2202 1.95 3 105 1.25 (1.13–1.38) 2173 5.11 3 107 1.28 (1.16–1.41) 594 2.08 3 104 1.44
Adenocarc. Smok.Adjust 541 0.012 1.21 (1.04–1.42) 683 8.33 3 105 1.31 (1.15–1.50) 270 0.004 1.42
Squamous Smok.Adjust 596 6.75 3 105 1.36 (1.17–1.58) 582 0.002 1.27 (1.09–1.47) 120 0.096 1.35
Small Cell Smok.Adjust 268 0.042 1.23 (1.01–1.50) 265 0.002 1.37 (1.12–1.67) 70 0.001 2.02
rs1051730
Overall Smok.Unadj 2202 9.26 3 107 1.27 (1.15–1.39) 2173 2.32 3 1011 1.35 (1.23–1.47) 594 2.41 3 105 1.42
Overall Smok.Adjust 2202 1.31 3 104 1.22 (1.10–1.36) 2173 6.57 3 107 1.28 (1.16–1.41) 594 6.89 3 104 1.40
Adenocarc. Smok.Adjust 541 0.011 1.22 (1.04–1.42) 683 7.30 3 105 1.32 (1.15–1.51) 270 0.008 1.38
Squamous Smok.Adjust 596 9.27 3 104 1.29 (1.11–1.51) 582 0.002 1.26 (1.09–1.47) 120 0.32 1.20
Small Cell Smok.Adjust 268 0.11 1.18 (0.96–1.44) 265 0.002 1.38 (1.13–1.70) 70 7.02 3 104 2.12
rs8034191
Overall Smok.Unadj 2202 1.13 3 105 1.23 (1.12–1.35) 2173 2.60 3 108 1.23 (1.12–1.35) 594 2.70 3 105 1.42
Overall Smok.Adjust 2202 0.002 1.18 (1.06–1.30) 2173 5.67 3 105 1.22 (1.11–1.35) 594 5.73 3 104 1.40
Adenocarc. Smok.Adjust 541 0.13 1.13 (0.96–1.31) 683 0.001 1.25 (1.09–1.43) 270 0.002 1.45
Squamous Smok.Adjust 596 0.006 1.23 (1.06–1.43) 582 0.007 1.23 (1.06–1.43) 120 0.39 1.17
Small Cell Smok.Adjust 268 0.24 1.13 (0.92–1.38) 265 0.005 1.33 (1.09–1.63) 70 0.004 1.89
Most notable SNPs from the NCI GWAS and SNPs identified as relevant for lung cancer risk in previous studies are shown. The lung cancer cases in the
small cell carcinomas, and other groups of different histologic types or mixed histologies. Smoking Unadjusted results are adjusted for age in five-year int
age at baseline for cohort study), gender, study (EAGLE, PLCO, ATBC, CPS-II), decade of birth (<1930, 1930–1940, 1940þ, MISSING) and four principal
and one each for EAGLE and ATBC). Smoking Adjusted, results are adjusted for the same variables as above plus smoking status (current, former, never), c
in ten-year intervals and number of years since quitting (1–5, 6–10, 11–20, 21–30, 30þ) for former smokers.
a 1 d.f. Wald test.
b OR, per-allele odds ratio; CI, 95% confidence interval.
c P-value of interaction between SNPs and decade of birth in the association with lung cancer risk overall and in each histology stratum. 1d.f. Wald t
The Environment and Genetics in Lung Cancer Etiology (EAGLE),
http://eagle.cancer.gov
ESPERR score, http://genome.ucsc.edu
The Estonian Genome Project, www.geenivaramu.eeresources/
groups/ed/programs/plco
GENEVA data set, http://www.ncbi.nlm.nih.gov/sites/
entrez?Db¼gap
Genotype Library and Utilities (GLU), http://code.google.com/p/
glu-genetics/
Online Mendelian Inheritance in Man (OMIM), http://www.ncbi.
nlm.nih.gov/Omim/
The Prostate, Lung, Colon, Ovary Screening Trial (PLCO), http://
prevention.cancer.gov/programs
SNP500Cancer, http://snp500cancer.nci.nih.gov/
STRUCTURE, http://pritch.bsd.uchicago.edu/structure.html
Tagzilla, http://tagzilla.nci.nih.gov/
References
1. Hung, R.J., McKay, J.D., Gaborieau, V., Boffetta, P., Hashibe,
M., Zaridze, D., Mukeria, A., Szeszenia-Dabrowska, N., Lissow-
ska, J., Rudnai, P., et al. (2008). A susceptibility locus for lung
cancer maps to nicotinic acetylcholine receptor subunit genes
on 15q25. Nature 452, 633–637.
2. Amos, C.I., Wu, X., Broderick, P., Gorlov, I.P., Gu, J., Eisen, T.,
Dong, Q., Zhang, Q., Gu, X., Vijayakrishnan, J., et al. (2008).
Genome-wide association scan of tag SNPs identiﬁes a suscep-
tibility locus for lung cancer at 15q25.1. Nat. Genet. 40,
616–622.
3. Thorgeirsson, T.E., Geller, F., Sulem, P., Rafnar, T., Wiste, A.,
Magnusson, K.P., Manolescu, A., Thorleifsson, G., Stefansson,
H., Ingason, A., et al. (2008). A variant associated with nico-
tine dependence, lung cancer and peripheral arterial disease.
Nature 452, 638–642.
4. McKay, J.D., Hung, R.J., Gaborieau, V., Boffetta, P., Chabrier,
A., Byrnes, G., Zaridze, D., Mukeria, A., Szeszenia-Dabrowska,
N., Lissowska, J., et al. (2008). Lung cancer susceptibility locus
at 5p15.33. Nat. Genet. 40, 1404–1406.
5. Wang, Y., Broderick, P., Webb, E., Wu, X., Vijayakrishnan, J.,
Matakidou, A., Qureshi, M., Dong, Q., Gu, X., Chen, W.V.,
et al. (2008). Common 5p15.33 and 6p21.33 variants inﬂu-
ence lung cancer risk. Nat. Genet. 40, 1407–1409.
6. Rafnar, T., Sulem, P., Stacey, S.N., Geller, F., Gudmundsson, J.,
Sigurdsson, A., Jakobsdottir, M., Helgadottir, H., Thorlacius, S.,
Aben, K.K., et al. (2009). Sequence variants at the TERT-
CLPTM1L locus associate withmany cancer types. Nat. Genet.
41, 221–227.
7. Gabrielson, E. (2006). Worldwide trends in lung cancer
pathology. Respirology 11, 533–538.
8. Gao, Y., Goldstein, A.M., Consonni, D., Pesatori, A.C.,
Wacholder, S., Tucker, M.A., Caporaso, N.E., Goldin, L., and
Landi, M.T. (2009). Family history of cancer and nonmalig-
nant lung diseases as risk factors for lung cancer. Int. J. Cancer
125, 146–152.
9. Li, X., and Hemminki, K. (2004). Inherited predisposition to
early onset lung cancer according to histological type. Int.
J. Cancer 112, 451–457.
10. Ambrosone, C.B., Rao, U., Michalek, A.M., Cummings, K.M.,
and Mettlin, C.J. (1993). Lung cancer histologic types and
family history of cancer. Analysis of histologic subtypes of
872 patients with primary lung cancer. Cancer 72, 1192–1198.690 The American Journal of Human Genetics 85, 679–691, Novemb11. Sellers, T.A., Elston, R.C., Atwood, L.D., and Rothschild, H.
(1992). Lung cancer histologic type and family history of
cancer. Cancer 69, 86–91.
12. Landi, M.T., Consonni, D., Rotunno, M., Bergen, A.W., Gold-
stein, A.M., Lubin, J.H., Goldin, L., Alavanja, M., Morgan, G.,
Subar, A.F., et al. (2008). Environment And Genetics in Lung
cancer Etiology (EAGLE) study: an integrative population-
based case-control study of lung cancer. BMC Public Health
8, e203.
13. The ATBC Cancer Prevention Study Group. (1994). The alpha-
tocopherol, beta-carotene lung cancer prevention study:
design, methods, participant characteristics, and compliance.
Ann. Epidemiol. 4, 1–10.
14. Hayes, R.B., Sigurdson, A., Moore, L., Peters, U., Huang, W.Y.,
Pinsky, P., Reding, D., Gelmann, E.P., Rothman, N., Pfeiffer,
R.M., et al. (2005). Methods for etiologic and early marker
investigations in the PLCO trial. Mutat. Res. 592, 147–154.
15. Calle, E.E., Rodriguez, C., Jacobs, E.J., Almon, M.L., Chao, A.,
McCullough,M.L., Feigelson, H.S., and Thun,M.J. (2002). The
American Cancer Society Cancer Prevention Study II Nutri-
tion Cohort: rationale, study design, and baseline characteris-
tics. Cancer 94, 2490–2501.
16. Power, C., and Elliott, J. (2006). Cohort proﬁle: 1958 British
birth cohort (National Child Development Study). Int. J. Epi-
demiol. 35, 34–41.
17. Sauter, W., Rosenberger, A., Beckmann, L., Kropp, S., Mittel-
strass, K., Timofeeva, M., Wolke, G., Steinwachs, A., Scheiner,
D., Meese, E., et al. (2008). Matrix metalloproteinase 1
(MMP1) is associated with early-onset lung cancer. Cancer
Epidemiol. Biomarkers Prev. 17, 1127–1135.
18. Omenn, G.S., Goodman, G., Thornquist, M., Grizzle, J.,
Rosenstock, L., Barnhart, S., Balmes, J., Cherniack, M.G.,
Cullen, M.R., Glass, A., et al. (1994). The beta-carotene and
retinol efﬁcacy trial (CARET) for chemoprevention of lung
cancer in high risk populations: smokers and asbestos-
exposed workers. Cancer Res. 54(7, Suppl), 2038s–2043s.
19. Holmen, J.M.K., Kruger, O., Langhammer, A., Lingaas Hol-
men, T., and Bratberg, G.H. (2003). The Nord-Trøndelag
Health Study 1995-97 (HUNT 2): Objectives, contents,
methods and participation. Norweg. J. Epidemiol. 13, 19–32.
20. Feyler, A., Voho, A., Bouchardy, C., Kuokkanen, K., Dayer, P.,
Hirvonen, A., and Benhamou, S. (2002). Point: myeloperoxi-
dase –463G–> a polymorphism and lung cancer risk. Cancer
Epidemiol. Biomarkers Prev. 11, 1550–1554.
21. Nelis, M., Esko, T., Magi, R., Zimprich, F., Zimprich, A.,
Toncheva, D., Karachanak, S., Pischakova, T., Balascak, I.,
Peltonen, L., et al. (2009). Genetic structure of Europeans:
a view from the North-East. PLoS ONE 4, e5472.
22. Yeager, M., Orr, N., Hayes, R.B., Jacobs, K.B., Kraft, P.,
Wacholder, S., Minichiello, M.J., Fearnhead, P., Yu, K., Chat-
terjee, N., et al. (2007). Genome-wide association study of
prostate cancer identiﬁes a second risk locus at 8q24. Nat.
Genet. 39, 645–649.
23. Pritchard, J.K., Stephens, M., and Donnelly, P. (2000). Infer-
ence of population structure using multilocus genotype
data. Genetics 155, 945–959.
24. Yu, K., Wang, Z., Li, Q., Wacholder, S., Hunter, D.J., Hoover,
R.N., Chanock, S., and Thomas, G. (2008). Population
substructure and control selection in genome-wide associa-
tion studies. PLoS ONE 3, e2551.
25. The International HapMap Project. (2003). Nature 426,
789–796.er 13, 2009
26. Price, A.L., Patterson, N.J., Plenge, R.M., Weinblatt, M.E.,
Shadick, N.A., and Reich, D. (2006). Principal components
analysis corrects for stratiﬁcation in genome-wide association
studies. Nat. Genet. 38, 904–909.
27. Higgins, J.P., and Thompson, S.G. (2002). Quantifying hetero-
geneity in a meta-analysis. Stat. Med. 21, 1539–1558.
28. Taylor, J., Tyekucheva, S., King, D.C., Hardison, R.C., Miller,
W., and Chiaromonte, F. (2006). ESPERR: learning strong
and weak signals in genomic sequence alignments to identify
functional elements. Genome Res. 16, 1596–1604.
29. Feldser, D.M., Hackett, J.A., and Greider, C.W. (2003). Telo-
mere dysfunction and the initiation of genome instability.
Nat. Rev. Cancer 3, 623–627.
30. Fernandez-Garcia, I., Ortiz-de-Solorzano, C., and Montuenga,
L.M. (2008). Telomeres and telomerase in lung cancer.
J. Thorac. Oncol. 3, 1085–1088.
31. Lantuejoul, S., Soria, J.C., Moro-Sibilot, D., Morat, L., Veyrenc,
S., Lorimier, P., Brichon, P.Y., Sabatier, L., Brambilla, C., and
Brambilla, E. (2004). Differential expression of telomerase
reverse transcriptase (hTERT) in lung tumours. Br. J. Cancer
90, 1222–1229.
32. Lantuejoul, S., Salon, C., Soria, J.C., and Brambilla, E. (2007).
Telomerase expression in lung preneoplasia and neoplasia.
Int. J. Cancer 120, 1835–1841.
33. viel-Ronen, S., Coe, B.P., Lau, S.K., da Cunha, S.G., Zhu, C.Q.,
Strumpf, D., Jurisica, I., Lam, W.L., and Tsao, M.S. (2008).
Genomic markers for malignant progression in pulmonary
adenocarcinoma with bronchioloalveolar features. Proc.
Natl. Acad. Sci. 105, 10155–10160.
34. Choi, J., Southworth, L.K., Sarin, K.Y., Venteicher, A.S., Ma,
W., Chang, W., Cheung, P., Jun, S., Artandi, M.K., Shah, N.,
et al. (2008). TERT promotes epithelial proliferation through
transcriptional control of a Myc- and Wnt-related develop-
mental program. PLoS Genet. 4, e10.
35. Sweet-Cordero, A., Tseng, G.C., You, H., Douglass, M., Huey,
B., Albertson, D., and Jacks, T. (2006). Comparison of gene
expression and DNA copy number changes in a murinemodel
of lung cancer. Genes Chromosomes Cancer 45, 338–348.
36. Jin, G., Xu, L., Shu, Y., Tian, T., Liang, J., Xu, Y., Wang, F.,
Chen, J., Dai, J., Hu, Z., et al. (2009). Common genetic variants
on 5p15.33 contribute to risk of lung adenocarcinoma in
a Chinese population. Carcinogenesis 30, 987–990.
37. Broderick, P., Wang, Y., Vijayakrishnan, J., Matakidou, A.,
Spitz, M.R., Eisen, T., Amos, C.I., and Houlston, R.S. (2009).
Deciphering the impact of common genetic variation on
lung cancer risk: a genome-wide association study. Cancer
Res. 69, 6633–6641.
38. Mushiroda, T., Wattanapokayakit, S., Takahashi, A., Nukiwa,
T., Kudoh, S., Ogura, T., Taniguchi, H., Kubo, M., Kamatani,
N., and Nakamura, Y. (2008). A genome-wide association
study identiﬁes an association of a common variant in TERT
with susceptibility to idiopathic pulmonary ﬁbrosis. J. Med.
Genet. 45, 654–656.
39. Tsakiri, K.D., Cronkhite, J.T., Kuan, P.J., Xing, C., Raghu, G.,
Weissler, J.C., Rosenblatt, R.L., Shay, J.W., and Garcia, C.K.
(2007). Adult-onset pulmonary ﬁbrosis caused by mutations
in telomerase. Proc. Natl. Acad. Sci. USA 104, 7552–7557.
40. Armanios, M.Y., Chen, J.J., Cogan, J.D., Alder, J.K., Ingersoll,
R.G., Markin, C., Lawson,W.E., Xie, M., Vulto, I., Phillips, J.A.,
III., et al. (2007). Telomerase mutations in families with idio-
pathic pulmonary ﬁbrosis. N. Engl. J. Med. 356, 1317–1326.The American41. Wang, Y., Kuan, P.J., Xing, C., Cronkhite, J.T., Torres, F.,
Rosenblatt, R.L., DiMaio, J.M., Kinch, L.N., Grishin, N.V.,
and Garcia, C.K. (2009). Genetic defects in surfactant protein
A2 are associated with pulmonary ﬁbrosis and lung cancer.
Am. J. Hum. Genet. 84, 52–59.
42. Vulliamy, T.J., Marrone, A., Knight, S.W., Walne, A., Mason,
P.J., and Dokal, I. (2006). Mutations in dyskeratosis congenita:
their impact on telomere length and the diversity of clinical
presentation. Blood 107, 2680–2685.
43. Yamaguchi, H., Calado, R.T., Ly, H., Kajigaya, S.,
Baerlocher, G.M., Chanock, S.J., Lansdorp, P.M., and Young,
N.S. (2005). Mutations in TERT, the gene for telomerase
reverse transcriptase, in aplastic anemia. N. Engl. J. Med.
352, 1413–1424.
44. Calado, R.T., Regal, J.A., Hills, M., Yewdell, W.T., Dalmazzo,
L.F., Zago, M.A., Lansdorp, P.M., Hogge, D., Chanock, S.J.,
Estey, E.H., et al. (2009). Constitutional hypomorphic telome-
rase mutations in patients with acute myeloid leukemia. Proc.
Natl. Acad. Sci. USA 106, 1187–1192.
45. Spitz,M.R., Amos, C., Dong, Q., Lin, J., andWu, X. (2008). The
CHRNA5-A3 region on chromosome 15q24-25.1 is a risk
factor both for nicotine dependence and for lung cancer.
J. Natl. Cancer Inst. 100, 1552–1556.
46. Hoffmann, D., Djordjevic, M.V., and Hoffmann, I. (1997). The
changing cigarette. Prev. Med. 26, 427–434.
47. Hecht, S.S. (1999). Tobacco smoke carcinogens and lung
cancer. J. Natl. Cancer Inst. 91, 1194–1210.
48. Thun, M.J., Lally, C.A., Flannery, J.T., Calle, E.E., Flanders,
W.D., and Heath, C.W., Jr. (1997). Cigarette smoking and
changes in the histopathology of lung cancer. J. Natl. Cancer
Inst. 89, 1580–1586.
49. Schuller, H.M., and Orloff, M. (1998). Tobacco-speciﬁc carci-
nogenic nitrosamines. Ligands for nicotinic acetylcholine
receptors in human lung cancer cells. Biochem. Pharmacol.
55, 1377–1384.
50. Le Marchand, L., Derby, K.S., Murphy, S.E., Hecht, S.S.,
Hatsukami, D., Carmella, S.G., Tiirikainen, M., and Wang, H.
(2008). Smokers with the CHRNA lung cancer-associated vari-
ants are exposed to higher levels of nicotine equivalents and
a carcinogenic tobacco-speciﬁc nitrosamine. Cancer Res. 68,
9137–9140.
51. LeMarchand, L., Sivaraman, L., Pierce, L., Seifried, A., Lum, A.,
Wilkens, L.R., and Lau, A.F. (1998). Associations of CYP1A1,
GSTM1, and CYP2E1 polymorphisms with lung cancer
suggest cell type speciﬁcities to tobacco carcinogens. Cancer
Res. 58, 4858–4863.
52. Thomas, G., Jacobs, K.B., Kraft, P., Yeager, M., Wacholder, S.,
Cox, D.G., Hankinson, S.E., Hutchinson, A., Wang, Z., Yu,
K., et al. (2009). A multistage genome-wide association study
in breast cancer identiﬁes two new risk alleles at 1p11.2 and
14q24.1 (RAD51L1). Nat. Genet. 41, 579–584.
53. Houlston, R.S., Webb, E., Broderick, P., Pittman, A.M., Di Ber-
nardo, M.C., Lubbe, S., Chandler, I., Vijayakrishnan, J.,
Sullivan, K., Peneg, S., et al. (2008). Meta-analysis of
genome-wide association data identiﬁes four new suscepti-
bility loci for colorectal cancer. Nat. Genet. 40, 1426–1435.
54. Eeles, R.A., Kote-Jarai, Z., Giles, G.G., Olama, A.A., Guy, M.,
Jugurnauth, S.K., Mulholland, S., Leongamornlert, D.A.,
Edwards, S.M., Morrison, J., et al. (2008). Multiple newly iden-
tiﬁed loci associated with prostate cancer susceptibility. Nat.
Genet. 40, 316–321.Journal of Human Genetics 85, 679–691, November 13, 2009 691
